Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01846442 · ClinicalTrials.gov registry record · Phase 3
Topical DHEA Against Vaginal Atrophy
A Phase 3 study of Vaginal Atrophy, sponsored by EndoCeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 218
- Enrollment target
- 8
- Study locations
NCT01846442 is a Phase 3 study of Vaginal Atrophy that has completed, run by EndoCeutics. The registered enrollment target is 218 participants, below the 332-participant average among 9 other Vaginal Atrophy trials with a reported enrollment target (34% lower). The trial reports 8 study locations across 4 states.
The verdict
NCT01846442, a Phase 3 study of Vaginal Atrophy, has completed, sponsored by EndoCeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 218 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine the dose-response of vaginal mucosa parameters to the local action of DHEA (Dehydroepiandrosterone) in postmenopausal women suffering from vaginal atrophy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DHEA (0.25%)
- DRUG DHEA (0.5%)
- DRUG DHEA (1.0%)
Study Locations (8)
Quebec
- EndoCeutics site # 10 - Montreal
- EndoCeutics site # 09 - Montreal
- EndoCeutics site # 08 - Shawinigan
- EndoCeutics site # 11 - Sherbrooke
Other
- EndoCeutics site # 02 - Québec
- EndoCeutics site # 01 - Québec
Ohio
- EndoCeutics site # 05 - Cleveland
Virginia
- EndoCeutics site # 03 - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01846442
The ClinicalTrials.gov registry entry for NCT01846442 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 332-participant average among 9 other Vaginal Atrophy trials with a reported enrollment target (34% lower). The listed sponsor is EndoCeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vaginal Atrophy appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01846442 reports 8 study locations spanning 4 distinct geographic areas - top geographies include Quebec, Other, Ohio.
Frequently Asked Questions
What is clinical trial NCT01846442 about?
NCT01846442 is a clinical study titled "Topical DHEA Against Vaginal Atrophy". The purpose of this study is to determine the dose-response of vaginal mucosa parameters to the local action of DHEA (Dehydroepiandrosterone) in postmenopausal women suffering from vaginal atrophy.
What is the current status of trial NCT01846442?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 218 participants. The study started on 2007-06. Estimated completion is 2008-10.
What conditions does trial NCT01846442 study?
This clinical trial studies the following conditions: Vaginal Atrophy.
What interventions are being tested in trial NCT01846442?
The interventions under investigation include: Placebo (DRUG), DHEA (0.25%) (DRUG), DHEA (0.5%) (DRUG), DHEA (1.0%) (DRUG).
Who is sponsoring clinical trial NCT01846442?
This trial is sponsored by EndoCeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01846442 being conducted?
This trial has 8 study locations across Ohio, Virginia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaginal Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause
COMPLETED · Phase 3
-
Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo
RECRUITING · Phase 4
-
Postpartum Vaginal Estrogen for Breastfeeding Patients
RECRUITING · Phase 4
-
ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy
RECRUITING · Phase 4
-
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
RECRUITING · NA
-
PRP Injections for Genitourinary Syndrome of Menopause
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.